Over the last eight years a number of workers, mainly from continental Europe, have reported promising results with D-penicillamine, in active chronic hepatitis, but so far no controlled trials have been reported. In the controlled trial reported here, the value of D-penicillamine was compared with prednisone in maintenance therapy, once the disease had been brought under control initially with larger doses of corticosteroids.
Thirty-five patients with active chronic hepatitis were selected from those seen in the Liver Clinic between December 1973 and October 1974. Active chronic hepatitis was diagnosed on the history of at least three months' duration with features, on liver biopsy, of chronic aggressive hepatitis, with or without cirrhosis. The patients were entered in the trial only when their disease had been brought under control biochemically as shown by a serum bilirubin <2.5 mg/100 ml, and serum aspartate transaminase <150 iu/l. These levels were reached with corticosteroids given initially in doses of 30 mg prednisone daily, reducing to 15 mg, with some patients receiving 75 mg azathioprine daily in addition.
The patients were then allocated to two groups using a random number system, one group on a maintenance treatment schedule of 1200 mg D-penicillamine daily and the other on 15 mg prednisone daily in divided doses. We did not attempt to make the trial double-blind because side-effects, if they arose, were likely to be distinctive. The group taking D-penicillamine were started on a daily dose of 600 mg, gradually increasing over three months to the full maintenance dose. The dosage of corticosteroids was gradually being reduced during the same three months' period. Patients with cirrhosis (determined histologically or by laparoscopy), and those with HBsAg in the serum, were randomized separately.
If the disease became out of control (serum bilirubin above 3.5 mg/100 ml or aspartate transaminase above 250 iu/l on two successive occasions within 14 days) or if evidence of severe drug toxicity side-effects developed, patients were withdrawn from the trial. Drug toxicity sideeffects necessitating withdrawal from the trial were considered to be bleeding or perforated peptic ulcer, vertebral collapse, diabetes requiring insulin, or psychosis in the prednisone group; and rash, leukopenia (<2000/mm3), thrombocytopenia (<40 000/mm3), intolerable nausea and vomiting, or proteinuria (>lg/24 h) in the Dpenicillamine group.
Findings During the Trial As the trial progressed, 9 of the 18 patients from the D-penicillamine group and 6 of the 17 patients from the prednisone group had to be withdrawn (Table 1 ). In each case the manifestations of drug toxicity side-effects disappeared when the drug was stopped. Only 2 patients were withdrawn from the D-penicillamine group because of lack of control of disease activity, and 7 developed drug toxicity side-effects. The 9 patients from this group who remained in the trial showed no deterioration in liver function tests at the end of one year's continuous treatment. In contrast, only one patient from the prednisone group was withdrawn because of drug toxicity side-effects, but 4 were withdrawn because the disease became out of control, and one because ofthe development ofcarcinomatosis. Although the reasons for withdrawal were different in the two groups, these differences did not achieve statistical significance, and neither did the total number of withdrawals.
An analysis of the mean values for serum bilirubin, aspartate transaminase and a globulin levels of the patients who remained in the two treatment groups after one year's continuous treatment also showed no significant statistical differences. The initial values for these patients on entry to the trial were also essentially similar. The mean serum cwruloplasmin in the D-penicillamine group was lower after a year's treatment Table 1 Patientswithdrawn from the trial, with duration of treatment and reasons for withdrawal than on entry, but this did not reach statistical significance (Table 2) . A comparison of patients with or without cirrhosis, or HBsAg, within and between the two groups, showed no significant differences in the number of patient withdrawals, the incidence of drug toxicity, or changes in liver function tests.
Comment
The currently adopted treatment for active chronic hepatitis, based on the results of a number of controlled trials (Cook etal. 1971 ,Murray-Lyon et al. 1973 , Summerskill et al. 1975 , is with corticosteroids, often in combination with azathioprine (Summerskill et al. 1975) . Although this treatment reduces the overall mortality and suppresses the inflammatory component of the liver lesion, there is no evidence to suggest that it affects established cirrhosis. Furthermore, the side-effects from both corticosteroids and azathioprine have been a problem in these series.
There is already considerable literature on the use of D-penicillamine in active chronic hepatitis. Alexander & Kludas (1969) used the drug in 2 patients with subacute hepatic necrosis, and Wiontzek (1970) in one with hepatitis and bridging necrosis. Five of the 6 patients treated by Lange et al. (1971) and all 1 1 treated by Schnack (1971) showed improvement in liver function tests and histology. In the three larger series which have been reported, Lange (1973) found clinical, biochemical, and histological improvement in 9 of 21 patients treated with 1.8 g Dpenicillamine a day, and Alexander & Willie (1974) found similar improvement in 15 of 34 patients, but in no case was cirrhosis reversed, and 12 patients had to stop the drug because of sideeffects. In 60 patients treated by Wildhirt (1974) , 38 % showed biochemical improvement, although in 25 % side-effects were a problem.
Unfortunately, it is difficult to assess these results, as none of the previous series was controlled. The present series is the first in which a prospective, randomly-allocated, controlled trial has been carried out. The results provide no evidence that the disease was less well controlled on D-penicillamine 1.2 g/day than on prednisone 15 mg/day. Indeed, control appeared slightly better on D-penicillamine, although this could not be proven statistically. However, side-effects with this drug proved a severe problem, necessitating withdrawal of 39% of the patients treated. Of these, proteinuria and nephrotic syndrome are perhaps the most serious, although only one case was seen in the present series and this was reversed when the drug was withdrawn. Sideeffects may be minimized by commencing with a low dosage, as was done in the present series, and recent studies in rheumatoid arthritis have also shown doses as low as 600 mg daily produce just as good a therapeutic effect as 1200 mg with fewer side-effects.
In conclusion, it is clear that, because of the frequency of toxic side-effects, D-penicillamine, at least in the present dosage, cannot be considered to be the treatment of choice in the maintenance therapy of patients with active chronic hepatitis. However, if prednisone (with or without azathioprine) becomes contraindicated because of the development of complications such as diabetes, osteoporosis, gastric ulceration, &c.
(or of leukopenia or neutropenia attributable to azathioprine), or if the disease fails to come under control, it would seem on the basis of our findings to be a useful alternative drug.
DISCUSSION
Dr Jain: Dr Williams, did you feel that because of the toxic side-effects there would not be the opportunity to treat enough patients for a sufficiently long time to know whether or not penicillamine would prevent cirrhosis, or prevent the development of further cirrhosis and portal hypertension?
Dr Williams: That would require a much longer trial and the patients taking part in the trial would have to be restricted to those who on initial investigation were shown not to have cirrhosis.
Professor Sherlock: Have any copper studies been made on these patients ?
Dr Williams: We saw no significant change in the serum czruloplasmin in the two groups. It was lower in the penicillamine-treated group, but not statistically so.
Dr J R Golding: I would be interested to hear from Dr Williams the details of the vasculitis in the penicillamine-treated patients.
Dr Williams: As I remember it, there was nothing specific about the vasculitis.
Dr H F H Hill: In treating rheumatoid arthritis, if a patient develops vasculitis we take that as an indication for using D-penicillamine, not the reverse.
Dr R N Mlaini (London): What proportion of the patients have antinuclear antibodies?
Dr Williams: We compared the two treatment groups with regard to every possible parameter, including the frequency and pattern of serum autoantibodies, but we could see no difference in the histological or biochemical findings. With respect to frequency, antinuclear factor is present in about 60-70% of patients with active chronic hepatitis.
Dr Maini: What happened to those levels?
Dr Williams: There was no significant chang~and they were still present at the end of the trial in the same sort of frequency as present initially.
Dr 1 Sterulieb (New York): This study brings up a chronic problem of nomenclature. After all those years spent discussing the classification of chronic active hepatitis, we are presented here with a series heavily loaded towards cirrhosisas Dr Williams has mentioneda group which is notoriously poor in its response to any type of treatment. This study will probably be applied to all types of chronic hepatitis, from persistent to other types, simply because of the projection that usually occursin the way that the Mayo Clinic studies were misapplied throughout the world, although they referred to a highly selected group of patients. Perhaps we ought to take time later to classify, or subclassify chronic active hepatitis, so that all of us use the same terms, as well as implying the same kind of process.
Dr Williams: The type of patient in the trial are those we see in this country, except that there was a slightly greater number ofcirrhotics because some of the patients who were included had been diagnosed for some time previously and maintained on treatment. At least a third of our patients have cirrhosis when they are first seen. It is wrong to say that these patients respond only poorly to treatment. They may show marked improvement, even when they have cirrhosis, if treated with prednisone and Imuran. Perhaps the only caveat to that would be the patients with Australia antigen in the serum, where there is some evidence that they do not respond as well. We had only 2 of those in this group, and we could also see no difference between those who had cirrhosis and those who were at an earlier stage, in terms of what happened in the trial. However, I must stress that patients were followed for only one year, but that, of course, is plenty of time to find out if they will relapse. Dr M I V Jayson (Bristol): The success rate in Dr Williams' trial is based on the number of withdrawals in the two groups. Could he please remind the nonhepatologists what the withdrawal rate might be from the placebo group who were brought into remission and the drug then withdrawn completely and followed over one year by the same parameters? Dr Williams: That is a good question, and perhaps Professor Sherlock would like to answer as her trial was the last one in which a placebo was used. Nobody would dare to use one now.
Professor Sherlock: No, it could not be done now. Dr Williams would not be doing a trial at all in this country if he waited for patients without cirrhosishe would not be in business without cirrhotic patients.
Dr Williams: Dr Jayson may be right in that some of them might stay in biochemical remission if they were taken off corticosteroids and not given anything else, but my own experience would suggest that the number would be small.
